Detailed answers about EYE2EYE CLINICS LIMITED, including incorporation, status, business activity, and accounts information.
When was EYE2EYE CLINICS LIMITED founded?
EYE2EYE CLINICS LIMITED was officially incorporated on 20 March 2008 and is registered under company number 06541518. Incorporation establishes the company as a legal entity registered at Companies House, allowing it to trade, enter contracts, and operate under UK company law.
What type of company is EYE2EYE CLINICS LIMITED?
Private Limited Company. This classification indicates the legal structure of the company, which determines the way it is governed, its liability, and regulatory obligations. A private limited company (Ltd) limits the personal liability of its shareholders.
What is the current status of EYE2EYE CLINICS LIMITED?
EYE2EYE CLINICS LIMITED's current status is Active. The company status indicates whether it is actively trading, dormant, or has been dissolved. Maintaining an active status is essential for legally conducting business, filing accounts, and maintaining credibility with partners and lenders.
What does EYE2EYE CLINICS LIMITED do?
EYE2EYE CLINICS LIMITED operates in the following sector: 96090 - Other service activities n.e.c.. This provides insight into the company's primary business activity and industry focus.
What is EYE2EYE CLINICS LIMITED's registered address?
The registered office address of EYE2EYE CLINICS LIMITED is 213 ROUNDHAY ROAD, LEEDS, WEST YORKSHIRE, LS8 4HS. This is the official address filed with Companies House for legal and statutory correspondence.
Is EYE2EYE CLINICS LIMITED financially stable?
The most recent accounts for EYE2EYE CLINICS LIMITED were made up to 31 March 2025, filed as TOTAL EXEMPTION FULL. Next accounts are due by 31 December 2026.
Does EYE2EYE CLINICS LIMITED have any charges or mortgages?
EYE2EYE CLINICS LIMITED has 1 registered charge, of which 1 is outstanding, 0 satisfied, and 0 part satisfied. Charges are typically registered when a company uses its assets as security for borrowing.